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Background 
Android fat distribution (abdominal obesity) is associated with insulin resistance, 
hepatic steatosis and greater secretion of large very low density lipoprotein (VLDL) 
particles in men. Since abdominal obesity is becoming increasingly prevalent in 
women we aimed to investigate the relationship between android fat and hepatic lipid 
metabolism in pre- and post-menopausal women.  
 
Methods and Results 
We used a combination of stable isotope tracer techniques to investigate intrahepatic 
fatty acid synthesis and partitioning in 29 lean and 29 abdominally obese women 
(android fat/total fat 0.065 (0.02-0.08) and 0.095 (0.08-0.11) respectively).  Thirty 
women were pre-menopausal aged 35-45 and they were matched for abdominal 
obesity with 28 post-menopausal women aged 55-65.  As anticipated, abdominal 
obese women were more insulin resistant with enhanced hepatic secretion of large 
(404±30 v 268±26 mg/kg lean mass, P<0.001) but not small VLDL (160±11 v 
142±13). However, post-menopausal status had a pronounced effect on the 
characteristics of small VLDL particles which were considerably triglyceride (TG)-
enriched (production ratio of VLDL2-TG:apolipoprotein B 30±5.3 v 19±1.6, P<0.05). 
In contrast to post-menopausal women, there was a tight control of hepatic fatty acid 
metabolism and TG production in pre-menopausal women, whereby oxidation (rs=-
0.49, P=0.006), de novo lipogenesis (rs=0.55, P=0.003) and desaturation (rs=0.48, 
P=0.012) were closely correlated with abdominal obesity-driven large VLDL-TG 
secretion rate.  
 
Conclusions 
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In women, abdominal obesity is a major driver of hepatic large VLDL particle 
secretion whereas post-menopausal status was characterised by increased small 
VLDL particle size. These data provide a mechanistic basis for the hyperlipidemia 
observed in post-menopausal obesity. 
 
Key words: apolipoproteins, cholesterol, lipids, lipoproteins, menopause, women 
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Introduction 
The menopause is associated with increased cardiovascular disease (CVD) and  
once women develop acute coronary symptoms, they have worse short- and long-
term outcomes than men 1. Many different factors contribute, including marked 
hormonal changes 2, changes in metabolic profile associated with increased risk of 
the metabolic syndrome 3, and relative increase in intra-abdominal fat with age 4. 
Accumulation of intra-abdominal fat is associated with increased waist circumference 
and liver fat 5, overproduction of very low-density lipoprotein (VLDL), and decreased 
catabolism of apolipoprotein (apo)B-containing particles in men 6. The catabolism of 
apoB-containing particles is partly determined by plasma apoC-III concentrations, 
and higher plasma apoC-III has been associated with dyslipidemia in obese men 7. 
Although abdominal obesity tends to be associated with obesity in men, data from 
the USA has been used to estimate that 40 % of women have an abdominal fat 
distribution pattern as defined by waist:hip ratio 8. 
Normally, fasting plasma TG is determined by two distinct sub-classes of 
VLDL 9; VLDL1 is larger and more TG-rich than VLDL2, the latter can either be 
secreted directly from the liver, or formed by the peripheral hydrolysis of VLDL1. 
Hypertriglyceridemia is associated with atherogenic dyslipidemia including the 
production of small dense LDL, lower HDL cholesterol and accumulation of 
postprandial TG-rich lipoproteins 10. In men with type 2 diabetes, the secretion of 
VLDL1 is associated with liver fat, hypertriglyceridaemia and increased atherogenic 
risk 11.  
Impaired hepatic fatty acid oxidation has been reported to be related to 
obesity and insulin resistance by some 12, 13 but not all 14. Few detailed studies have 
investigated VLDL1 and VLDL2 kinetics in women and none have compared the 
kinetics of VLDL or apoC-III in pre- and post-menopausal women. We hypothesized 
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that VLDL1-TG and –apoB secretion would be higher in abdominally-obese 
compared with abdominally lean women and aimed to investigate the effect of 
menopause status on this relationship by measuring hepatic de novo fatty acid 
synthesis (DNL), oxidation and desaturation in relation to VLDL1 and VLDL2 kinetics 
in pre- and post-menopausal women. 
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Materials and Methods  
Subjects. We recruited sixty healthy White Caucasian women from local advertising 
and the Oxford Biobank as previously reported 15 equally into pre- and post-
menopausal groups aged 35-45 and 55-65 respectively. The age groups ensured 
peri-menopausal women were not included and postmenopausal status was defined 
as absence of menses for at least 12 months and FSH > 30 IU/L. Since we also 
wished to investigate the effect of android fat (abdominal obesity), we used waist 
circumference, a marker of android fat, to facilitate recruitment of women into groups 
with low or high android fat. For simplicity we have referred to the group with low 
android fat as ‘lean’.  A waist circumference of  ≥ 80 cm was selected as the proxy 
measure of high android fat, with increased risk of CVD in Europid women defined 
by the International Diabetes Federation 16 and additionally, we recruited women into 
small waist (<80cm, n=30), or large waist (80 – 84 cm, n=5; 85 – 91 cm, n=5; and 92 
– 110 cm, n=5) categories in both menopausal groups. This was to ensure a good 
range of android fat in our cohort, and ensure exact matching of abdominal obesity 
between menopausal groups. Other inclusion and exclusion criteria have been 
previously described in a study relating to energy intake in a sub-set of the 
participants 15 but briefly, women were excluded if they had any condition or 
treatment that would affect metabolic or hormonal status (including smoking, 
diabetes or hormone replacement therapy), or had BMI <18.5 or >34.9. Smokers or 
women exceeding alcohol consumption guidelines of 2-3 units per day were also 
excluded 17. All participants gave informed, written consent and the study was 
approved by the Oxfordshire Clinical Research Ethics Committee.  Participants 
attended the Clinical Research Unit prior to the metabolic day in order to be given 
deuterated water for consumption the evening before the study day, and to give a 
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blood sample for background isotopic enrichment measurements relating to the 
measurement of de novo lipogenesis (DNL, see below). 
 
Measurement of liver, subcutaneous and visceral fat and body composition. 
Intra-hepatic fat was measured by magnetic resonance spectroscopy, visceral and 
subcutaneous fat were measured by magnetic resonance imaging after an overnight 
fast and within two weeks of the study day 18, whole body composition and fat 
distribution (eg android and gynoid fat) were measured using DEXA 15.  
 
Metabolic study day. Participants arrived after an overnight fast and after 
consuming deuterated water (2H2O, in order to measure de novo lipogenesis, DNL) 
(3 g/kg body water) at 8 and 10 pm the evening before the study day and then 
continued to consume enriched water (2.5 g per 500mL water), in order to achieve 
and maintain a plasma water enrichment of 0.3 % 19.  A cannula was placed in an 
antecubital vein in order to take blood samples for the estimation of DNL in VLDL1- 
and VLDL2-palmitate, and background isotopic enrichments for the kinetic studies. 
Another cannula was placed in the contra lateral arm to administer intravenous 
boluses of [2H3]leucine (7 mg/kg) and [2H5]glycerol (500 mg), whilst an intravenous 
infusion of [U-13C]palmitic acid, potassium salt complexed with albumin 20 at 0.03 
µmol/kg/min, was started. Blood samples were taken for a further 8h and VLDL1 and 
VLDL2 isolated from plasma using density gradient ultracentrifugation 20. Due to 
technical problems, one participant did not receive the palmitate infusion, one 
participant’s infusion was stopped early and one participant did not complete the 
metabolic study day. 
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Biochemical analyses. Blood samples were drawn into heparinized syringes 
(Sarstedt, Leicester, UK) and plasma rapidly separated at 4°C. Plasma metabolites 
were analyzed enzymatically 20, insulin was measured by radioimmunoassay 
(Millipore (UK) Ltd, Watford, UK) and HOMA-IR was calculated as an index of insulin 
resistance 21. A time averaged area-under-the-curve (AUC) for plasma 3-
hydroxybutyrate (3OHB) and non-esterified fatty acids (NEFA) was calculated from 
hourly values taken during the study. Serum steroids (cortisol, 
dehydroepiandrosterone (DHEA) and androstenedione were measured by liquid 
chromatography/tandem mass spectrometry (LC/MS-MS) using a Waters Xevo mass 
spectrometer with Acquity uPLC system as described previously 22. [2H5]glycerol in 
plasma, VLDL1 and VLDL2-TG (to trace TG) and [2H3]leucine in plasma, VLDL1-and 
VLDL2-apoB (to trace whole particles) were measured by GC-MS 23. [U-13C]palmitic 
acid was measured in plasma NEFA and VLDL1 and VLDL2-TG by GC-MS 20 and the 
proportion of FAs in VLDL-TG that were derived from non-systemic sources was 
calculated 20, assuming that 16:0 is representative of all FAs. Mathematical 
modelling of VLDL kinetics (VLDL1-TG, VLDL2-TG, VLDL1-apoB, VLDL2-apoB 
production and clearance) was calculated from [2H5]glycerol and [2H3]leucine 
enrichments in plasma and lipoprotein fractions 11. See Figures S1 and S2 for 
examples of raw data used for modelling. VLDL-TG production rates were corrected 
for lean mass in order to consider delivery of TG to muscle as previously described 
24 but not corrected when considering hepatic FA trafficking. Total plasma apoC-III 
and apoC-III in plasma devoid of apoB-containing particles were measured using a 
Hydragel LP CIII Electroimmunodiffusion kit (Sebia, France) with appropriate 
standards and quality controls according to the manufacturer’s instructions. By 
difference, we calculated apoC-III concentrations in apoB-containing particles (apoC-
III LpB). ApoCIII kinetic modelling was carried out as previously described 25 and 
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assumes (consistent with previous studies, and earlier radiotracer studies), that 
apoCIII exchanges between VLDL and HDL particles, and therefore that measuring 
apoCIII kinetics in plasma is valid.   
 
The ratio of [U-13C]16:1n-7/[U-13C]16:0 in VLDL1 and VLDL2-TG was determined as 
a short-term index of hepatic stearoyl-CoA desaturase (SCD) activity (the ‘isotopic 
desaturation index’) and also the SCD16 and SCD18 fatty acid ratios 26. FA methyl 
esters prepared from VLDL1 and VLDL2-TG FAs 20 were analysed by GC 13 to 
quantify 16:0 and 16:1n-7, and by GC-IRMS to measure isotopic enrichment 26. 
Hepatic DNL was measured on the study day, based on the incorporation of 2H in 
plasma water (Finnigan GasBench-II (ThermoFisher Scientific, UK) and into VLDL1- 
and VLDL2-TG palmitate using GC-MS 27. For simplicity, this is referred to as ‘%DNL’ 
and represents synthesis of fatty acids from precursors such as sugars and amino 
acids 28. 
 
FA rate of appearance (RaNEFA) was calculated from the [U-13C]16:0 infusion rate 
and enrichment in the plasma NEFA fraction and RdNEFA was assumed to equal 
RaNEFA 24. 
 
Statistical analysis. Statistical analysis was performed using SPSS Statistics 19 
(IBM, SPSS products, Chertsey, UK). Two-way ANOVA was used to determine the 
effect of abdominal obesity and menopausal status (fixed factors) on each 
dependent variable, and interaction between the fixed factors. A significant 
interaction term indicated that the relationship between the dependent variable and 
abdominal obesity was significantly different in pre- and post-menopausal women. 
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Associations between variables were carried out using Spearman’s rank correlation 
coefficient (univariate analysis).  
 
In order to visualise relationships between metabolic variables, we plotted significant 
correlations between metabolic and anthropometric variables related to hepatic FA 
partitioning using ‘hive plots’ 29. Each variable is represented by a node and the 
nodes are joined by blue (significant positive correlations) or red (significant negative 
correlations) lines. The nodes are placed on three duplicated radial axes which 
represent grouped variables (anthropometric and metabolic variables/VLDL1 or 
VLDL2). The axes are duplicated in order to allow for representation of correlations 
within the variable group e.g. there are lines joining the isotopic desaturation index 
and %DNL in VLDL1 for pre- and post-menopausal women, representing significant 
positive correlations.  
 
Power calculation. Using data from a study of the reproducibility of relevant kinetic 
parameters (VLDL TG and apoB100 secretion rates, VLDL-TG clearance rate, Ra 
NEFA 30, and DNL 19, separate power calculations were carried out and the numbers 
in pre- and post-menopausal groups to detect a 40% difference with power of 0.80 at 
α of 0.05 were 4, 8, 9, 10 and 15 respectively (in each group). A difference of 40 % 
was considered to be clinically significant and was within the range of differences 
previously reported in other studies11.  
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Results 
Sixty women were recruited: mean age was 41.0 years (range 35-45) for pre-
menopausal and 58.1 years (55-64) for post-menopausal women. Mean age when 
divided according to abdominal obesity was 49.3 (35-64) and 49.3 (35-63) for lean 
and abdominally obese women respectively. Plasma FSH concentrations ranged 
from 3.0-21.3 and 46.5-125 IU/L in pre- and post-menopausal women respectively 
(confirming menopausal status). Fifty-eight women from whom DEXA scans were 
available are included in this study, divided according to menopause status and 
android fat measurement (corrected for total fat), for statistical analyses. Lean 
women had a mean android fat of 0.065 (SD 0.013) and abdominally obese women 
had a mean value of 0.094 (SD 0.008). Gynoid fat was significantly lower, and intra-
abdominal fat was significantly higher in post-menopausal women, despite being 
matched for abdominal obesity (Table 1). Liver fat was generally low although six 
women, all abdominally-obese, had values of >5 %. BMI was not significantly 
different between menopausal groups and ranged from 21.5 to 33.0 kg/m2 in 
abdominally-obese and 19.5 to 27.6kg/m2 in abdominally lean women. Thus some 
abdominally lean women would be classified as overweight by BMI, and some 
abdominally-obese women would be classified as lean by BMI. 
Post-menopausal women had significantly higher concentrations of plasma 
total, LDL, non-HDL cholesterol, apoCIII-LpB, plasma apoB and systolic BP than 
pre-menopausal women (Table 2). Women with abdominal obesity were more insulin 
resistant with a more adverse lipid profile (higher non-HDL cholesterol, plasma TG, 
VLDL1- and VLDL2-TG concentrations). One post-menopausal woman had impaired 
fasting glucose. 
The rate of disappearance of FAs (RdNEFA), expressed per kg lean mass 
was significantly higher in post- compared to pre-menopausal women (Table 3). 
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Release of FAs into plasma (RaNEFA) per unit weight of adipose tissue was lower in 
women with abdominal obesity, but VLDL1-TG and VLDL1-apoB production were 
significantly higher. The ratio of VLDL2-TG direct production: VLDL2-apoB production 
was significantly higher in post- compared to pre-menopausal women, indicating 
production of larger particles.  
There were no significant positive correlations between age and liver fat, 
VLDL1-TG and VLDL2-TG direct production, VLDL1 and VLDL2 direct apoB 
production, or VLDL1 and VLDL2-TG:apoB production ratios within menopausal 
groups. 
Plasma apoC-III concentrations positively correlated with apoC-III production 
rate (rs=0.59, P=9.0 x 10-7) but not clearance rate, indicating plasma apoC-III 
concentrations were determined by production rate. Plasma, HDL- and apoC-III 
associated with lipoprotein B-containing particle (apoC-III LpB) concentrations were 
not affected by abdominal obesity, but plasma apoC-III LpB concentrations were 
higher in post-menopausal women. 
Overall, mean %DNL was less than 10% in VLDL1- and VLDL2-palmitate (data 
not shown) and when corrected for flux from the liver, was not significantly different 
between menopausal groups, but was higher with abdominal obesity. Menopause 
status affected the relationship between abdominal obesity and 3OHB:NEFA, and 
abdominal obesity per se had a strong influence on factors related to FA partitioning 
(Table 4). Of note, the systemic FA contribution to VLDL1-TG production was 
significantly higher in abdominally-obese women, in line with higher VLDL1-TG 
secretion. 
To explore FA partitioning in relation to metabolic and anthropometric 
measurements, we tabulated univariate correlations between relevant variables in 
pre- and post-menopausal women (selected data in Tables 5-8 and complete 
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analysis in Tables S1-S4). The data are illustrated in hive plots (Figure 1) which 
clearly show that the patterns of correlations are quite different in pre- and post-
menopausal women. In particular, the density of correlations in the top left of the 
figure for pre-menopausal women (Figure 1A, anthropometric and metabolic 
variables with VLDL2 metabolism) is markedly less for post-menopausal women 
(Figure 1B). Correlations relating to %DNL and VLDL production are shown in Figure 
2A and B and between %DNL and plasma 3OHB in Figure 2C and D. The most 
marked univariate correlations relating to hepatic FA partitioning were between the 
isotopic desaturation index in VLDL1 and VLDL2-TG and plasma 3OHB AUC (Figure 
2E and F). VLDL-ApoB and -TG production were highly correlated for VLDL1 and 
less so for VLDL2 (Figure 3). Serum cortisol concentrations were negatively 
correlated with WHR in pre- (rs=-0.38, P=0.04) but not post-menopausal women. 
There was a significant correlation between abdominal fat and liver fat (rs=0.50, 
P<0.001, n=60). The importance of menopausal status in this relationship is shown 
in the hive plots and Tables 5-8 which showed, remarkably, that a significant 
correlation between liver fat and abdominal obesity was observed only in pre-
menopausal women. 
We also took the opportunity to examine metabolic variables according to liver 
fat content because of the importance of liver fat with respect to the metabolic 
complications of obesity 32. The median value in the cohort of 60 women was 0.85%. 
Of the 50 % of women with lower liver fat, seventeen were pre-menopausal and 
thirteen were post-menopausal. In general, significant effects reflected those found 
by considering women according to abdominal obesity (see Tables S5-S7). However, 
the effect of liver fat on LDL, HDL and non-HDL cholesterol as well as VLDL-TG 
production was less than for abdominal obesity. 
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Discussion 
Using a combination of stable isotope tracer techniques, we investigated kinetic 
parameters of apoB, apoC-III and TG metabolism in pre- and post-menopausal 
women. We report for the first time that menopausal status is a determinant of 
hepatic TG flux through enhancement of adipose tissue NEFA flux, altered intra-
hepatic FA partitioning and secretion of larger VLDL2. VLDL-TG secretion is normally 
dependent on VLDL-apoB100 secretion 33 but we found that  VLDL2-TG secretion 
after the menopause was dissociated from VLDL2-apoB production. Systemic FAs 
were the major source of VLDL2-TG in all women, but both systemic and non-
systemic FAs contributed to greater VLDL2-TG secretion in post-menopausal women. 
We also report for the first time that VLDL1-TG secretion is higher in abdominally-
obese women. Our main findings are summarised in Figure S3.  
VLDL1 and VLDL2 metabolism have not previously been measured in relation 
to menopausal and abdominal obesity status in women.  We measured two aspects 
of VLDL secretion; VLDL-apoB secretion rate, which measures whole particle 
secretion, and VLDL-TG secretion, which tracks the lipid component. Using these 
two parameters we were also able to estimate the relative sizes of VLDL1 and VLDL2 
at the point of hepatic secretion. VLDL1 and VLDL2 secretion rates were correlated 
but in agreement with previous findings, their metabolism was independent 34 as 
shown in hive plots.  
VLDL1-TG and VLDL1-apoB production rates were significantly higher in the 
abdominally-obese compared to abdominally lean women. Higher VLDL1-TG 
secretion was attributable to both systemic and non-systemic FA. There are no 
previous comparable studies but in lean and obese pre-menopausal women there 
were no differences in total VLDL-apoB or VLDL-TG secretion 35, 36. Another study in 
pre-menopausal women found higher total VLDL-TG production in upper-body obese 
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compared with lean women 37, although production was not corrected for any 
measure of body mass.  
VLDL2-TG direct production was higher in post- compared to pre-menopausal 
women, due to production of TG-enriched VLDL2. This has not been reported 
previously and the relevance is as yet, not clear, but small rather than large VLDL is 
implicated in atherosclerosis progression 38. VLDL2-TG production was higher in 
post-menopausal women than men matched for plasma TG concentrations 24 and as 
discussed by the authors, VLDL2 is more efficiently converted to LDL than VLDL1. 
Moderate hypercholesterolemia arises principally from overproduction of VLDL2 
particles in men 39; our study was not designed to measure LDL kinetics but higher 
plasma and LDL cholesterol concentrations after the menopause were not 
accompanied by an increase in VLDL2-apoB production. 
Menopausal status did not affect VLDL1 or VLDL2 clearance, in contrast to the 
work of Mittendorfer 40. VLDL kinetics are sensitive to intra-abdominal and liver fat 
content 32, and discrepancies between published studies may be due to liver fat 
content, and/or kinetic parameters not corrected for adiposity or lean mass. Although 
estrogen per se may affect VLDL kinetics 41, other factors such as the changes in 
body composition accompany estrogen deficiency. We found increased 
concentrations of plasma total and LDL cholesterol, and apoB which are typical 
features of dyslipidaemia in post-menopausal women 42. Additionally, we found 
significantly higher apoC-III LpB, in post-menopausal women. Since apoC-III plays a 
pivotal role in the development of hypertriglyceridemia 7, apoC-III may play a role in 
the development of dyslipidemia in older, post-menopausal women.  
Higher RdNEFA in post-menopausal women is consistent with the finding that 
exogenous estrogen reduced NEFA flux in post-menopausal women 43. This 
suggests that higher NEFA flux in post-menopausal women is a result of estrogen 
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depletion.  RaNEFA, when corrected for fat mass was significantly lower with 
increasing abdominal obesity, in agreement with the concept of downregulated 
adipose tissue FA trafficking in obesity with reduced expression of lipolytic genes 
such as hormone sensitive lipase and adipose triglyceride lipase 44. The relationship 
between obesity, insulin resistance and lipolysis is not clear in the literature and has 
been elegantly reviewed 45. At a whole body level, lipolysis was similar in lean and 
abdominally obese groups but the contribution of systemic FA to increased VLDL1-
TG was significantly higher in abdominally-obese women, as was the contribution of 
non-systemic FA, with a tendancy for increased de novo hepatic FA secretion 
indicating an upregulation of secretion of FA from all sources. Higher secretion of de 
novo palmitate has previously been found in obese hypertriglyceridaemic men 
compared with lean normo-lipidaemic men and women 46. Our findings of inverse 
correlations between plasma 3OHB and %DNL in VLDL1-TG are in agreement with 
studies in healthy men and women 47. Moreover, we found strong inverse 
correlations between the isotopic desaturation index in VLDL1- and VLDL2-TG and 
plasma 3OHB in the whole cohort. These two variables are not obviously related but 
provide the first evidence of a clear divergence of FA partitioning in humans in vivo 
such that hepatic desaturation of FAs was low when FA oxidation was high (and vice 
versa).  
Serum cortisol concentrations were negatively correlated with WHR in pre- 
but not post-menopausal women. Cortisol status has previously been inversely 
related to WHR in women, although menopause status was not defined; this has 
been explained by a higher local clearance rate of cortisol in visceral fat, which has 
more glucocorticoid receptors than subcutaneous fat 48. However, we found no 
correlation between serum cortisol concentrations and intra-abdominal fat area. In 
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agreement with previous studies of ageing 49 serum cortisol concentrations were 
higher in post-menopausal women. 
Strengths of our study include the unique combination of kinetic and 
anthropometric measurements in large groups of well-matched women but a 
limitation is the cross-sectional design. Therefore we cannot ascribe causality to any 
of the correlations found. Post-menopausal women were older and therefore any 
effects of ‘menopausal status’ do not reflect a difference in hormone concentrations, 
but rather the natural course of events (menopause plus ageing with accompanying 
changes in body fat distribution). Indeed, post-menopausal women had equal 
abdominal obesity but higher intra-abdominal fat and less gynoid fat, demonstrating 
a change in body fat distribution 4. Given the importance of estrogen in determining 
body fat distribution and direct effects on lipid metabolism, it may have been 
insightful to measure serum estrogen concentrations although it is clear that many 
factors beyond sex hormones contribute to lipid and lipoprotein metabolism 50. The 
study design meant that we were able to look at correlations within each menopausal 
group. We also analysed our data according to liver fat and we found that overall, the 
results were similar to when we divided according to abdominal obesity. This is in 
contrast to findings in individuals with a large range of liver fat 32 where liver fat was 
found to be more discriminatory. However, we found that abdominal obesity in 
women was more related to impaired VLDL-TG secretion than liver fat. This 
suggests that other intra-hepatic factors are contributing to VLDL-TG secretion. 
We did not include a comparator group of men but other groups have 
compared lipoprotein metabolism in men and women. One study found that VLDL-
TG secretion rate was not significantly different in men and women 50 whereas 
another found that VLDL2-TG but not VLDL1-TG secretion rate was higher in women 
than men. We have previously reported no difference in the postprandial contribution 
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of dietary and non-systemic FA to VLDL-TG between insulin-sensitive men and 
women 13. However, lipoprotein  metabolism is dependent on a many factors and 
accumulation of excess body fat seems to affect lipid kinetics differently in men and 
women as recently discussed 50. Total body fat and body fat distribution are obvious 
differences between men and women, and this study has highlighted the importance 
of body fat distribution in women.  
 
Conclusions 
VLDL1 and VLDL2 metabolism is complex in women and hive plots illustrate that the 
patterns of associations with metabolic variables are different between menopausal 
groups. A lack of significant correlation between hepatic VLDL2-TG and VLDL2-apoB 
production is intriguing and requires further study. Abdominal obesity was 
characterized by increased CVD risk factors such as VLDL1-TG and –apoB 
production, liver fat and non-HDL cholesterol. Interestingly, this was observed 
despite a considerable overlap in BMI between abdominally lean and abdominally-
obese groups. Our study is the first to report that VLDL1-TG secretion is significantly 
higher in abdominally-obese women and accounts for increased plasma VLDL1-TG 
and plasma TG concentrations. This is important because there is increasing 
evidence that there is a causal relationship between TG-mediated pathways and 
coronary heart disease 51. Weight gain in post-menopausal women is likely to impact 
on both VLDL1-TG and VLDL2-TG secretory pathways with consequent implications 
for CVD risk. 
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Figure legends 
 
Figure 1. Significant correlations between variables relating to VLDL-TG metabolism 
represented as hive plots for pre-menopausal (Figure 1A) and post-menopausal 
(Figure 1B) women. Each variable is represented by a node and the nodes are 
joined by blue (significant positive correlations) or red (significant negative 
correlations) lines. The thickness of the line represents the strength of the correlation. 
The nodes are placed on three duplicated radial axes which represent grouped 
variables (anthropometric and metabolic variables/VLDL1 or VLDL2). Individual 
nodes are coded as indicated and specific correlation coefficients are given in 
Supplemental Material.  Node codes: A, liver fat (%); B, total body fat (kg); C, 
android fat/total fat; D, gynoid fat/total fat; E, visceral fat (cm
2
); F, subcut fat (cm
2
); G, 
NEFA (µmol/l); H, 3OHB (AUC); I, HOMA-IR; K, VLDL‐TG SCD isotopic index; M, 
VLDL‐TG SCD18 index; O, VLDL‐TG 18:2n‐6 (%); Q, VLDL‐TG production per day; 
S, VLDL‐TG SCD16; U, VLDL‐TG DNL (%); W, VLDL‐TG production/apoB 
production.  Abbreviations: subcut, subcutaneous; NEFA, plasma non-esterified fatty 
acids; 3OHB, plasma 3-hydroxybutyrate; HOMA-IR, homeostatic model assessment 
of insulin resistance; VLDL, very low-density lipoprotein; TG, triglyceride; SCD, 
stearoyl-CoA desaturase; SCD18, 18:1 n-9 / 18:0 ratio in VLDL-TG; SCD16, 16:1 n-
7/16:0 ratio in VLDL-TG; DNL, hepatic de novo lipogenesis; apoB, apolipoprotein B. 
 
Figure 2.  Correlations between VLDL1-TG production (mg/day) and the proportion 
(%) of DNL fatty acids VLDL1-TG (Figure 2A), VLDL2-TG direct production (mg/day) 
and the proportion (%) of DNL fatty acids VLDL2-TG (Figure 2B), the proportion (%) 
of DNL fatty acids VLDL1-TG and the AUC for plasma 3-hydroxybutyrate (µmol/L) 
(Figure 2C), the proportion (%) of DNL fatty acids VLDL2-TG and the AUC for plasma 
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3-hydroxybutyrate (µmol/L) (Figure 2D), and the association between plasma 3-
hydroxybutyrate concentrations (µmol/L) and the isotopic desaturation index 
([U13C16:1n-7 / U13C16:0]*1000) in VLDL1-TG (Figure 2E) and VLDL2-TG (Figure 2F) 
in pre-(●) and post- (○) menopausal women. 
 
Figure 3. Correlations between VLDL1-apoB production (mg/day) and VLDL1-TG 
production (mg/day) (Figure 3A), VLDL2-apoB production (mg/day) and VLDL2-TG 
direct production (mg/day) (Figure 3B) in pre-(●) and post- (○) menopausal women. 
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Table 1. Body composition in women according to menopausal status and abdominal obesity 
 
Pre-menopausal 
(n=30) 
Post-menopausal 
(n=30)†  
Lean 
(n=29) 
Abdominally obese 
(n=29) 
Pmeno PAbd obesity 
Waist (cm) 83.5 (1.8) 82.1 (1.4) 77.1 (0.86) 88.6 (1.5) NS <0.001 
BMI (kg/m2) 24.9 (0.6) 24.8 (0.4) 23.2 (0.36) 26.6 (0.54) NS <0.001 
WHR 0.85 (0.01) 0.84 (0.01) 0.82 (0.009) 0.87 (0.01) NS 0.001 
Gynoid fat 5.3 (0.25) 5.0 (0.14) 4.6 (0.17) 5.6 (0.20) NS <0.001 
Gynoid fat ¥ 0.24 (0.07) 0.21 (0.05) 0.25 (0.006) 0.20 (0.004) <0.01 <0.001 
Android:gynoid ratio 0.35 (0.02) 0.39 (0.02) 0.27 (0.015) 0.47 (0.015) <0.05 <0.001 
Intra-ab fat (cm2) 40.7 (4.1) 53.3 (5.5) 26.5 (2.0) 67 (4.6) <0.05 <0.001 
Subcut fat (cm2) 225.0 (17.0) 241.0 (14.0) 181 (11) 282 (14) NS <0.001 
Fat mass (kg) 23.2 (1.3) 23.4 (0.9) 19.0 (0.72) 27.6 (0.88) NS <0.001 
Lean mass (kg) 42.4 (0.9) 39.4 (0.8) 39.5 (0.89) 42.4 (0.87) <0.05 <0.001 
Fat:lean mass 0.54 (0.03) 0.60 (0.02) 0.49 (0.21) 0.65 (0.015) * <0.05 <0.001 
Liver fat (%) 0.78 (0.25–11.5) 0.97 (0.44–6.8) 0.61 (0.25-2.1) 1.3 (0.32-11.5) NS <0.001 
 
Data presented as mean (sem) or median (range); † n=30 for post-menopausal women apart from data derived from DEXA measurements 
which were n=28 (gynoid fat, android: gynoid ratio, fat mass, lean mass and fat:lean mass).  ¥ corrected for total fat mass in order to investigate 
differences in body fat distribution. Abbreviations: BMI, body mass index; WHR, waist to hip ratio; Intra-ab fat, intra-abdominal fat; Subcut fat, 
subcutaneous fat; Statistical significance based on 2-way ANOVA: Pmeno Statistical significance for an effect of menopausal status; PAbd obesity 
Statistical significance for an effect of abdominal obesity; *P<0.05 for interaction between abdominal obesity and menopausal status.
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Table 2. Biochemical and metabolic variables in women according to menopausal status and abdominal obesity 
 Pre-menopausal 
(n=30) 
Post-menopausal 
(n=30) † 
Lean 
(n=29) 
Abdominally obese 
(n=29) 
Pmeno PAbd obesity 
Total chol (mmol/l) 4.9 (0.1)  5.9 (0.2) 5.3 (0.2) 5.5 (0.2) <0.001 NS 
LDL chol (mmol/l) 2.9 (0.1) 3.8 (0.2) 3.1 (0.1) 3.5 (0.2) <0.001 <0.05 
HDL chol (mmol/l) 1.6 (0.1) 1.7 (0.1) 1.8 (0.07) 1.4 (0.06) NS <0.001 
Non-HDL chol (mmol/l) 3.3 (0.1) 4.2 (0.2) 3.5 (0.15) 4.0 (0.18) <0.001 <0.01 
TG (mmol/l) 0.9 (0.1) 0.9 (0.1) 0.72 (0.05) 1.09 (0.15) NS <0.01 
VLDL1-TG (µmol/l) 142 (33–2083) 226 (82–1090) 181 (26) 369 (72) NS 0.001 
VLDL2-TG (µmol/l) 142 (39–1061) 189 (78–488) 154 (17) 247 (34) NS <0.01 
Plasma apoC-III (mg/l) 28.7 (1.9) 33.8 (1.5) 31 (1.7) 31 (2.0) 0.06 NS 
apoCIII-LpB (mg/l) 11.9 (0.9) 15.5 (1.0) 13 (0.9) 14 (1.1) <0.01 NS 
ApoC-III Lp nonB (mg/l) 16.8 (1.4) 18.4 (1.0) 18 (1.2) 17 (1.2) NS NS 
Plasma apoB (g/l) 0.73 (0.51-1.27) 0.89 (0.51–1.37) 0.78 (0.51–1.23) 0.88 (0.51–1.27) 0.001 <0.05 
VLDL1-apoB (g/l) 0.006 (0.001–0.05) 0.007 (0.004–0.03) 0.005 (0.001–0.03) 0.008 (0.004–0.05) NS <0.05 
VLDL2-apoB (g/l) 0.018 (0.004–0.13) 0.023 (0.01–0.06) 0.018 (0.004–0.04) 0.023 (0.01–0.13) NS <0.05 
Insulin (mU/l) 11.5 (0.9) 10.5 (0.4) 9.2 (0.44) 12.8 (0.79) NS <0.001 
Glucose (mmol/l) 5.0 (0.1) 5.1 (0.1) 4.9 (0.08) 5.2 (0.07) NS <0.05 
HOMA-IR 3.1 (0.3) 2.8 (0.1) 2.4 (0.14) 3.5 (0.24) NS <0.01 
NEFA (µmol, AUC) 591 (33) 626 (25) 633 (32) 579 (27) NS NS 
Plasma 3OHB (µmol, AUC) 156 (13.5) 130 (13.5) 160 (14) 126 (13) NS <0.05 
Systolic BP (mmHg) 114 (2.2) 126 (2.5) 119 (2.8) 121 (2.5) 0.001 NS 
Diastolic BP (mmHg) 75 (1.4) 75 (2.3) 75 (1.7) 76 (1.8) NS NS 
 
Data presented as mean (sem) or median (range); † n=30 for post-menopausal women apart from AUC measurements for NEFA and 3OHB 
which are n=29 
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Abbreviations: Chol, cholesterol; LDL, low density-lipoprotein; HDL, high density-lipoprotein; VLDL, very low-density lipoprotein; ApoB, 
apolipoprotein; apoC-III LpB, apoC-III associated with lipoprotein B containing particles; BP, blood pressure; HOMA-IR, estimate of insulin 
resistance; Statistical significance based on 2-way ANOVA: Pmeno Statistical significance for an effect of menopausal status; PAbd obesity Statistical 
significance for an effect of abdominal obesity; no significant interaction between abdominal obesity and menopausal status was found. 
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Table 3. Kinetic estimates relating to NEFA, VLDL and apoC-III metabolism in women according to menopausal status and abdominal obesity  
 
Pre-menopausal Post-menopausal Lean Abdominally obese Pmeno PAbd obesity 
RaNEFA (µmol.min-1 per kg fat mass) 9.1 (0.8) n=30 10.0 (0.6) n=26 11 (0.8) n=28 8.2 (0.6) n=28 NS 0.01 
RdNEFA (µmol.min-1 per kg lean mass) 4.6 (0.3) n=30 5.8 (0.3) n=26 5.1 (0.4) n=28 5.3 (0.3) n=28 <0.05
5 
NS 
RaNEFA (µmol.min-1) 193 (12) n=30 220 (12) n=28 197 (13) n=28 219 (11) n=28 0.05 NS 
VLDL1-TG Prod (mg/kg lean mass) 332 (35) n=26 350 (27) n=26 268 (26) n=24 404 (30) n=28 NS 0.001 
VLDL2-TG dirProd (mg/kg lean mass) 129 (12) n= 26 174 (12) n=26 142 (13) n=24 160 (11) n=28 <0.01 0.07 
VLDL2-TG indirProd (mg/ kg lean mass) 100 (21) n=25 110 (14) n=26 88 (17) n=24 120 (18) n=27 NS NS 
VLDL1-TG FCR (pools/day) 29 (3.2) n=26 26 (2.5) n=27 31 (2.9) n=24 25 (2.8) n=28 NS NS 
VLDL2-TG FCR (pools/day) 22 (2.3) n=26 26 (2.7) n=27 26 (2.6) n=24 22 (2.4) n=28 NS NS 
VLDL1-TG FTR (pools/day) 6.8 (1.0) n=25 7.5 (1.0) n=27 7.9 (1.2) n=24 6.6 (0.8) n=27 NS NS 
VLDL1-TG FDC (pools/day) 22 (3.2) n=26 18 (2.3) n=27 23 (3.0) n=24 18 (2.7) n=28 NS NS 
VLDL1-apoB FDC (pools/day) 9.2 (1.7) n=28 7.5 (1.5) n=28 8.5 (1.5) n=26 8.5 (1.7) n=29 NS NS 
VLDL1-apoB FTR (pools/day) 8.6 (1.0) n=27 8.2 (0.8) n=28 8.5 (1.0) n=26 8.1 (0.8) n=28 NS NS 
VLDL1-apoB FCR (pools/day) 18 (1.9) n=28 16 (1.5) n=28 17 (1.6) n=26 16 (1.8) n=29 NS NS 
VLDL2-apoB FCR (pools/day) 8.6 (0.8) n=28 7.7 (0.8) n=28 8.7 (0.8) n=26 7.8 (0.8) n=29 NS NS 
VLDL1-apoB Prod (mg per day) 344 (38) n=28 316 (27) n=28 253 (26) n=26 397 (34)* n=29 NS 0.001 
VLDL2-apoB dirProd (mg per day) 304 (21) n= 28 278 (20) n=28 269 (19) n=26 311 (22)* n=29 NS NS 
VLDL2-apoB indirProd (mg per day) 194 (34) n=28 163 (19) n=28 130 (18) n=25 215 (31) n=28 NS <0.05 
VLDL1-TG Prod:VLDL1 apoB Prod‡ 42 (2.8) n=26 49 (5.9) n=27 45 (4.2) n=24 47 (5.2) n=28  NS NS 
VLDL2-TG dirProd:VLDL2 apoB Prod‡ 19 (1.6) n=26 30 (5.3) n=27 21 (2.1) n=24 28 (5.1) n=28 <0.05 NS 
ApoC-III FCR (pools/day) 1.1 (0.1) n=30 1.1 (0.1) n=30 1.1 (0.1) n=29 1.0 (0.09) n=29 NS NS 
ApoC-III PR (mg per kg/day) 1.5 (0.2) n=30 1.7 (0.1) n=30 1.6 (0.2) n=29 1.4 (0.1) n=29 NS NS 
 
Data presented as mean (sem) 
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Abbreviations: Ra, rate of appearance; Rd, rate of disappearance; TG, triacylglycerol; ApoB, Apolipoprotein B100; lean, lean tissue; Prod, 
production; dirprod, direct production; indirprod, indirect production FCR, fractional clearance rate; FTR, fractional transfer rate; FDC, fractional 
direct clearance; ‡mg/day; Statistical significance based on 2-way ANOVA: Pmeno Statistical significance for an effect of menopausal status; PAbd 
obesity Statistical significance for an effect of abdominal obesity; *P<0.05 for interaction between abdominal obesity and menopausal status. 
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Table 4 Variables relating to fatty acid metabolism in women according to menopausal status and abdominal obesity 
 
 Pre-menopausal Post-menopausal Lean Abdominally obese Pmeno 
PAbd 
obesity 
Non-systemic FA - VLDL1-
TG (%) 
15.5 (3.2) n=27 14.2 (2.6) n=23 9.5 (1.9) n=24 20 (3.4) n=26 NS <0.05 
Non-systemic FA - VLDL2-
TG (%) 
17.2 (3.4) n=27 18.6 (2.6) n=23 11 (2.1) n=24 24 (3.3) n=26 NS <0.01 
Non-systemic FA 
contribution to VLDL1-TG 
production (mg/day) 
2943 (803) n=24 1678 (367) n=21 1180 (349) n=20 3290 (747) n=25 NS <0.001 
Non-systemic FA 
contribution to VLDL2-TG 
direct production (mg/day) 
1028 (197) n=24 1192 (181) n=21 668 (146) n=20 1453 (185)* n=25 <0.05 <0.001 
Systemic FA contribution 
to VLDL1-TG production 
(mg/day) 
11814 (1307) n=24 11449 (956) n=21 9613 (946) n=20  13269 (1183) n=25 NS <0.05 
Systemic FA contribution 
to VLDL2-TG direct 
production (mg/day) 
4563 (511) n=24 5594 (389) n=21 4709 (441) n=20 5312 (486) n=25 0.06 NS 
VLDL1-TG isotopic 
desaturation indexa 
9.2 (3.0-29.2) n=30 10.5 (3.6-68.2) n=28 8.2 (3-29) n=28 10.6 (36-68) n=29 NS 0.06 
VLDL2-TG isotopic 
desaturation indexa 
9.0 (3.2-28.5) n=30 10.2 (4.9-60.7) n=28 8.5 (3.5-28) n=28 10.6 (4.9-61) n=29 NS <0.05 
VLDL1-16:0 TG 
synthesised de novo 
(mg/day)a 
118 (4.9-1444) n=26 283 (27.2-2564) n=26 114 (4.9-1444) n=23 309 (12-2564) n=28 NS 0.06 
VLDL2-16:0 TG 
synthesised de novo 
(mg/day)a 
62 (0.42-351) n=26 102 (7.4-583) n=26 61 (42-351) n=23 117 (7.4-583) n=28 NS <0.05 
3OHB/NEFA  0.24 (0.012) n=30 0.22 (0.02) n=29 0.25 (0.02) n=29 0.21 (0.02) n=29** NS NS 
 
Data presented as mean (SEM) or median (range). Statistical significance based on 2-way ANOVA: Pmeno Statistical significance for an effect of 
menopausal status; PAbd obesity Statistical significance for an effect of abdominal obesity; *P<0.05, **P<0.01 for a statistically significant 
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interaction between abdominal obesity and menopausal status.  Abbreviations: FA, fatty acid; VLDL, very low-density lipoprotein, TG, 
triglyceride; 3OHB, 3-hydroxybutyrate; NEFA, non-esterified fatty acids
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Table 5.  Correlation coefficients (rs) for pre-menopausal women between selected variables relating to VLDL1 metabolism, liver fat and intra-abdominal fat 
 
 
Total 
body fat 
(kg) 
Android/
tot fat 
(kg) 
Gynoid/ 
tot fat 
(kg) 
Visceral 
fat (cm2) 
Subcut 
fat (cm2) 
HOMA-
IR 
Plasma 
NEFA* 
(µmol/L) 
Plasma 
3OHB* 
(µmol/L) 
VLDL1-
TG 
prod/d 
VLDL1-
TG SCD 
iso index 
VLDL1-
TG 
SCD16  
VLDL1-
TG 
SCD18 
VLDL1-
TG DNL 
(%) 
VLDL1-
TG 
18:2n-6 
(%) 
VLDL1-
TG 
prod/apo
B prod 
Liver fat 
(%) 
0.57 
P=0.001 
0.63 
P<0.001 
-0.39 
P=0.034 
0.71 
P<0.001 
0.47 
P=0.009 
0.63 
P<0.001 
-0.07 
P=0.702 
-0.42 
P=0.022 
0.40 
P=0.045 
0.41 
P=0.025 
-0.05 
P=0.803 
-0.33 
P=0.078 
0.47 
P=0.009 
-0.19 
P=0.323 
-0.29 
P=0.150 
Total 
body fat 
(kg) 
 
0.68 
P<0.001 
-0.63 
P<0.001 
0.80 
P<0.001 
0.90 
P<0.001 
0.36 
P=0.052 
-0.00 
P=0.982 
-0.33 
P=0.077 
0.61 
P=0.001 
0.39 
P=0.039 
0.17 
P=0.370 
-0.13 
P=0.480 
0.49 
P=0.006 
-0.35 
P=0.055 
-0.07 
P=0.739 
Android/
tot fat 
(kg) 
  
-0.74 
P<0.001 
0.78 
P<0.001 
0.63 
P<0.001 
0.53 
P=0.003 
-0.10 
P=0.596 
-0.37 
P=0.046 
0.53 
P=0.005 
0.35 
P=0.057 
0.09 
P=0.629 
-0.20 
P=0.300 
0.32 
P=0.085 
-0.07 
P=0.699 
-0.07 
P=0.719 
*AUC 
Abbreviations: tot, total; Subcut, subcutaneous; HOMA_IR, homeostatic model assessment of insulin resistance; NEFA, non-esterified fatty acids; 3OHB, 3-
hydroxybutyrate; VLDL, very low-density lipoprotein; TG, triglyceride, SCD, Stearoyl-CoA desaturase 1; prod, production; d, day; iso, isotopic; SCD16, ratio of 
16:1n-7 / 16:0; SCD18, ratio 18:1n-9/18:0;  DNL, de novo lipogenesis; AUC, area under the curve. See Supplemental Material for full statistical analysis.
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Table 6.  Correlation coefficients (rs) for pre-menopausal women between selected variables relating to VLDL2 metabolism, liver fat and intra-abdominal fat. 
 
 
Total 
body fat 
(kg) 
Android/
tot fat 
(kg) 
Gynoid/ 
tot fat 
(kg) 
Visceral 
fat (cm2) 
Subcut 
fat (cm2) 
HOMA-
IR 
Plasma 
NEFA* 
(µmol/L) 
Plasma 
3OHB* 
(µmol/L) 
VLDL2-
TG 
prod/d 
VLDL2-
TG SCD 
iso index 
VLDL2-
TG 
SCD16  
VLDL2-
TG 
SCD18 
VLDL2-
TG DNL 
(%) 
VLDL2-
TG 
18:2n-6 
(%) 
VLDL2-
TG 
prod/apo
B prod 
Liver fat 
(%) 
0.57 
P=0.001 
0.63 
P<0.001 
-0.39 
P=0.034 
0.71 
P<0.001 
0.47 
P=0.009 
0.63 
P<0.001 
-0.07 
P=0.702 
-0.42 
P=0.022 
0.21 
P=0.306 
0.38 
P=0.040 
0.01 
P=0.952 
-0.37 
P=0.042 
0.42 
P=0.021 
-0.19 
P=0.323 
-0.29 
P=0.150 
Total 
body fat 
(kg) 
 
0.68 
P<0.001 
-0.63 
P<0.001 
0.80 
P<0.001 
0.90 
P<0.001 
0.36 
P=0.052 
-0.00 
P=0.982 
-0.33 
P=0.077 
0.51 
P=0.007 
0.41 
P=0.023 
0.21 
P=0.257 
-0.24 
P=0.202 
0.41 
P=0.023 
-0.25 
P=0.177 
0.23 
P=0.255 
Android/
tot fat 
(kg) 
  
-0.74 
P<0.001 
0.78 
P<0.001 
0.63 
P<0.001 
0.53 
P=0.003 
-0.10 
P=0.596 
-0.37 
P=0.046 
0.29 
P=0.145 
0.36 
P=0.052 
0.12 
P=0.516 
-0.31 
P=0.092 
0.22 
P=0.240 
-0.05 
P=0.791 
0.11 
P=0.580 
*AUC 
Abbreviations: tot, total; Subcut, subcutaneous; HOMA_IR, homeostatic model assessment of insulin resistance; NEFA, non-esterified fatty acids; 3OHB, 3-
hydroxybutyrate; VLDL, very low-density lipoprotein; TG, triglyceride, SCD, Stearoyl-CoA desaturase 1; prod, production; d, day; iso, isotopic; SCD16, ratio of 
16:1n-7 / 16:0; SCD18, ratio 18:1n-9/18:0;  DNL, de novo lipogenesis; AUC, area under the curve. See Supplementary Material for full statistical analysis.
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Table 7.  Correlation coefficients (rs) for post-menopausal women between selected variables relating to VLDL1 metabolism, liver fat and intra-abdominal fat 
 
 
Total 
body fat 
(kg) 
Android/
tot fat 
(kg) 
Gynoid/ 
tot fat 
(kg) 
Visceral 
fat (cm2) 
Subcut 
fat (cm2) 
HOMA-
IR 
Plasma 
NEFA* 
(µmol/L) 
Plasma 
3OHB* 
(µmol/L) 
VLDL1-
TG 
prod/d 
VLDL1-
TG SCD 
iso index 
VLDL1-
TG 
SCD16  
VLDL1-
TG 
SCD18 
VLDL1-
TG DNL 
(%) 
VLDL1-
TG 
18:2n-6 
(%) 
VLDL1-
TG 
prod/apo
B prod 
Liver fat 
(%) 
0.28 
P=0.150 
0.26 
P=0.184 
-0.42 
P=0.028 
0.61 
P<0.001 
0.26 
P=0.192 
0.23 
P=0.232 
0.00 
P=0.994 
0.09 
P=0.647 
0.05 
P=0.797 
-0.11 
P=0.595 
-0.42 
P=0.023 
-0.26 
P=0.173 
0.04 
P=0.838 
0.11 
P=0.578 
0.26 
P=0.200 
Total 
body fat 
(kg) 
 
0.78 
P<0.001 
-0.57 
P=0.002 
0.73 
P<0.001 
0.86 
P<0.001 
0.29 
P=0.133 
-0.09 
P=0.648 
0.19 
P=0.326 
0.34 
P=0.093 
-0.01 
P=0.949 
-0.13 
P=0.512 
0.22 
P=0.279 
0.01 
P=0.967 
0.32 
P=0.106 
0.35 
P=0.077 
Android/
tot fat 
(kg) 
  
-0.76 
P<0.001 
0.72 
P<0.001 
0.69 
P<0.001 
0.35 
P=0.064 
-0.35 
P=0.072 
-0.14 
P=0.475 
0.57 
P=0.003 
0.23 
P=0.246 
-0.21 
P=0.287 
-0.05 
P=0.788 
0.19 
P=0.342 
0.29 
P=0.143 
0.25 
P=0.225 
*AUC 
Abbreviations: tot, total; Subcut, subcutaneous; HOMA_IR, homeostatic model assessment of insulin resistance; NEFA, non-esterified fatty acids; 3OHB, 3-
hydroxybutyrate; VLDL, very low-density lipoprotein; TG, triglyceride, SCD, Stearoyl-CoA desaturase 1; prod, production; d, day; iso, isotopic; SCD16, ratio of 
16:1n-7 / 16:0; SCD18, ratio 18:1n-9/18:0;  DNL, de novo lipogenesis;AUC, area under the curve. See Supplementary Material for full statistical analysis.
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Table 8.  Correlation coefficients (rs) for post-menopausal women between selected variables relating to VLDL1 metabolism, liver fat and intra-abdominal fat 
 
Total 
body fat 
(kg) 
Android/
tot fat 
(kg) 
Gynoid/ 
tot fat 
(kg) 
Visceral 
fat (cm2) 
Subcut 
fat (cm2) 
HOMA-
IR 
Plasma 
NEFA* 
(µmol/L) 
Plasma 
3OHB* 
(µmol/L) 
VLDL2-
TG 
prod/d 
VLDL2-
TG SCD 
iso index 
VLDL2-
TG 
SCD16  
VLDL2-
TG 
SCD18 
VLDL2-
TG DNL 
(%) 
VLDL2-
TG 
18:2n-6 
(%) 
VLDL2-
TG 
prod/apo
B prod 
Liver fat 
(%) 
0.28 
P=0.150 
0.26 
P=184 
-0.42 
P=0.028 
0.61 
P<0.001 
0.26 
P=0.192 
0.23 
P=0.232 
0.00 
P=0.994 
0.09 
P=0.647 
-0.15 
P=0.470 
-0.05 
P=0.797 
-0.46 
P=0.013 
-0.44 
P=0.016 
0.11 
P=0.564 
0.15 
P=0.450 
0.11 
P=0.594 
Total 
body fat 
(kg) 
 
0.78 
P<0.001 
-0.57 
P=0.002 
0.73 
P<0.001 
0.86 
P<0.001 
0.29 
P=0.133 
-0.09 
P=0.648 
0.19 
P=0.326 
0.18 
P=0.380 
-0.03 
P=0.875 
-0.12 
P=0.554 
-0.04 
P=0.842 
0.13 
P=0.518 
0.27 
P=0.171 
0.30 
P=0.133 
Android/
tot fat 
(kg) 
  
-0.76 
P<0.001 
0.72 
P<0.001 
0.69 
P<0.001 
0.35 
P=0.064 
-0.35 
P=0.072 
-0.14 
P=0.475 
0.20 
P=0.341 
0.20 
P=0.329 
-0.23 
P=0.244 
-0.13 
P=0.506 
0.16 
P=0.423 
0.22 
P=0.275 
0.31 
P=0.123 
*AUC 
Abbreviations: tot, total; Subcut, subcutaneous; HOMA_IR, homeostatic model assessment of insulin resistance; NEFA, non-esterified fatty acids; 3OHB, 3-
hydroxybutyrate; VLDL, very low-density lipoprotein; TG, triglyceride, SCD, Stearoyl-CoA desaturase 1; prod, production; d, day; iso, isotopic; SCD16, ratio of 
16:1n-7 / 16:0; SCD18, ratio 18:1n-9/18:0;  DNL, de novo lipogenesis; AUC, area under the curve. See Supplementary Material for full statistical analysis.
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